E-ISSN 2534-9821
 
2023, Vol: 7, Issue: 6
7 / 6Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Copyright Transfer Form

Case Report

Online Publishing Date:
21 / 08 / 2022

 


Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab

Timothy Patrick McCann, Hatem Elabd, Stephen P Beerman.


Abstract
Introduction: Nivolumab is an immune checkpoint inhibitor (ICI) in a class of immunomodulators used to treat various cancers, including melanoma. Here we present ICI-related cardiomyopathy leading to patient death.
Case Report: An 88-year-old female receiving therapy for metastatic melanoma with immune checkpoint inhibitor Nivolumab presented with acute hypoxic respiratory failure secondary to new onset acute combined systolic and diastolic heart failure. She had no known cardiac history and was on minimal medication before the presentation. After extensive workup, including pleural fluid analysis, a cardiac magnetic resonance, and left heart catheterization, no other cause could be attributed to her cardiac dysfunction other than an adverse medication event due to immunomodulation therapy with Nivolumab.
Discussion: Cardiomyopathy is a rare but potentially life-threatening complication of ICI therapy and should be considered when discussing treatment modalities with patients, especially in high-risk populations.

Key words: Nivolumab, immune checkpoint inhibitor, cardiomyopathy, melanoma


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Timothy Patrick McCann
Articles by Hatem Elabd
Articles by Stephen P Beerman
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. 2022; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669

Web Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. https://www.mdpub.net/?mno=18345 [Access: April 04, 2024]. doi:10.5455/IJMRCR.172-1650130669

AMA (American Medical Association) Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. 2022; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669


Vancouver/ICMJE Style

McCann TP, Elabd H, Beerman SP. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep. (2022), [cited April 04, 2024]; 6(14): 44-47. doi:10.5455/IJMRCR.172-1650130669


Harvard Style

McCann, T. P., Elabd, . H. & Beerman, . S. P. (2022) Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. Int J Med Rev Case Rep, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669


Turabian Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. 2022. Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. International Journal of Medical Reviews and Case Reports, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669


Chicago Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. "Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab." International Journal of Medical Reviews and Case Reports 6 (2022), 44-47. doi:10.5455/IJMRCR.172-1650130669


MLA (The Modern Language Association) Style

McCann, Timothy Patrick, Hatem Elabd, and Stephen P Beerman. "Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab." International Journal of Medical Reviews and Case Reports 6.14 (2022), 44-47. Print. doi:10.5455/IJMRCR.172-1650130669


APA (American Psychological Association) Style

McCann, T. P., Elabd, . H. & Beerman, . S. P. (2022) Dilated Cardiomyopathy from Immune Checkpoint Inhibitor, Nivolumab. International Journal of Medical Reviews and Case Reports, 6 (14), 44-47. doi:10.5455/IJMRCR.172-1650130669


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports  (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500